NCT00887159 2021-01-05
A Randomized Phase II Study of Cisplatin and Etoposide in Combination With Either Hedgehog Inhibitor GDC-0449 or IGF-1R MOAB IMC-A12 for Patients With Extensive Stage
National Cancer Institute (NCI)
Phase 2 Completed
Clinical Trials
9 trialsNCT01232452 2019-09-20
A Study in Non-Small Cell Lung Cancer
Eli Lilly and Company
Phase 2 Completed
NCT01263782 2019-05-15
BATTLE-FL: Front-Line Biomarker-Integrated Treatment Study in Non Small Cell Lung Cancer
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00955305 2018-06-06
Paclitaxel, Carboplatin, and Bevacizumab With or Without Cixutumumab in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer
National Cancer Institute (NCI)
Phase 2 Terminated
NCT00870870 2018-06-01
A Study of IMC-A12 (Cixutumumab) With and Without Other Standard Chemotherapies in Participants With Lung Cancer Who Have Not Received Chemotherapy Before
Eli Lilly and Company
Phase 2 Completed
NCT01160458 2018-04-10
Phase II Study of IMC-A12 in Patients With Mesothelioma Who Have Been Previously Treated With Chemotherapy
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT00986674 2014-09-26
Carboplatin and Paclitaxel Combined With Cetuximab and/or IMC-A12 in Patients With Advanced Non-Small Cell Lung Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00778167 2014-05-21
Erlotinib Hydrochloride With or Without Cixutumumab in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT00970580 2013-09-16
A Study of BIIB022 in Combination With Paclitaxel and Carboplatin in Subjects With Non-Small Cell Lung Cancer
Biogen
Phase 1 Completed